---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Contraindications/Warnings/Precautions/Adverse effects"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Contraindications/Warnings/Precautions/Adverse effects. Covers Warnings and precautions. 17 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/contraindications-warnings-precautions-adverse-effects"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Contraindications/Warnings/Precautions/Adverse effects

<a id="heading-2.1.2.7"></a>

## 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

#### FDA-approved prescribing information, boxed warning, contraindications, and REMS

> “We have never completed a pivotal clinical trial or submitted an NDA to the FDA or similar drug approval filings to comparable foreign authorities.”
> “For example, the most common side effects we have seen in patients treated with palazestrant in our clinical trials are nausea, fatigue, vomiting, constipation, headaches, and neutropenia.”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

<a id="topic-2.1.2.7.1-2"></a>

#### Treatment-emergent and treatment-related adverse events: phase 1/2 monotherapy at 60 and 120 mg

> “Most patients (95.3%) who received the RP2D of 120 mg/day experienced ≥ 1 TEAE of any grade, most commonly nausea (62.8%), vomiting (29.1%), and fatigue (25.6%).”
> “Grade 3 TEAEs were reported in 21 (24.4%) patients, most commonly vomiting (n = 4 [4.7%]), neutropenia, nausea, and fatigue (n = 3 each [3.5%]).”
> “Eight (9.3%) patients treated with 120 mg/day palazestrant also experienced grade 4 TEAEs, including neutropenia (n = 6), acute respiratory failure (n = 1), and 1 patient experienced 3 grade 4 events (pulmonary embolism, diverticulitis, and acute left ventricular failure).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

| Adverse event, n (%) | 60 mg, any grade (n = 30) | 120 mg, any grade (n = 86) | 120 mg, grade 3 | 120 mg, grade 4 |
| --- | --- | --- | --- | --- |
| TEAE: nausea | “14 (46.7)” | “54 (62.8)” | “3 (3.5)” | “0” |
| TEAE: vomiting | “5 (16.7)” | “25 (29.1)” | “4 (4.7)” | “0” |
| TEAE: fatigue | “13 (43.3)” | “22 (25.6)” | “3 (3.5)” | “0” |
| TEAE: neutropenia | “2 (6.7)” | “21 (24.4)” | “3 (3.5)” | “6 (7.0)” |
| TEAE: headache | “7 (23.3)” | “17 (19.8)” | “0” | “0” |
| TEAE: constipation | “6 (20.0)” | “15 (17.4)” | “0” | “0” |
| TEAE: diarrhea | “6 (20.0)” | “12 (14.0)” | “0” | “0” |
| TRAE: nausea | “10 (33.3)” | “47 (54.7)” | “3 (3.5)” | “0” |
| TRAE: vomiting | “3 (10.0)” | “21 (24.4)” | “2 (2.3)” | “0” |
| TRAE: fatigue | “9 (30.0)” | “17 (19.8)” | “2 (2.3)” | “0” |
| TRAE: neutropenia | “0” | “18 (20.9)” | “3 (3.5)” | “5 (5.8)” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.7.1-3"></a>

#### Adverse events by dose: posted registry results of the phase 1/2 trial

| Adverse event, affected/at risk (%) | 60 mg QD | 90 mg QD | 120 mg QD | 300 mg QD |
| --- | --- | --- | --- | --- |
| Total serious adverse events | “4/33 (12.12%)” | “2/6 (33.33%)” | “16/83 (19.28%)” | “2/7 (28.57%)” |
| Febrile neutropenia (serious) | “0/33 (0.00%)” | “0/6 (0.00%)” | “2/83 (2.41%)” | “1/7 (14.29%)” |
| Nausea | “14/33 (42.42%)” | “2/6 (33.33%)” | “55/83 (66.27%)” | “6/7 (85.71%)” |
| Vomiting | “5/33 (15.15%)” | “1/6 (16.67%)” | “24/83 (28.92%)” | “5/7 (71.43%)” |
| Diarrhoea | “6/33 (18.18%)” | “0/6 (0.00%)” | “14/83 (16.87%)” | “1/7 (14.29%)” |
| Fatigue | “13/33 (39.39%)” | “0/6 (0.00%)” | “24/83 (28.92%)” | “4/7 (57.14%)” |
| Neutrophil count decreased | “2/33 (6.06%)” | “0/6 (0.00%)” | “16/83 (19.28%)” | “2/7 (28.57%)” |
| Alanine aminotransferase increased | “0/33 (0.00%)” | “0/6 (0.00%)” | “11/83 (13.25%)” | “1/7 (14.29%)” |
| Aspartate aminotransferase increased | “0/33 (0.00%)” | “0/6 (0.00%)” | “13/83 (15.66%)” | “0/7 (0.00%)” |
| Sinus bradycardia | “0/33 (0.00%)” | “0/6 (0.00%)” | “7/83 (8.43%)” | “2/7 (28.57%)” |
| Photopsia | “0/33 (0.00%)” | “2/6 (33.33%)” | “5/83 (6.02%)” | “3/7 (42.86%)” |

Source: [ClinicalTrials.gov NCT04505826 results](https://clinicaltrials.gov/study/NCT04505826?tab=results)

<a id="topic-2.1.2.7.1-4"></a>

#### Neutropenia: phase 1/2 monotherapy

> “Treatment-related grade 4 neutropenia occurred in 5 (5.8%) patients.”
> “Of the 6 patients with grade 4 neutropenia, 3 events resolved with a dose interruption (1 week) followed by a dose reduction (to 60 mg/day in 1 patient and to 90 mg/day in 2 patients); these patients continued treatment with no further neutropenia.”
> “While grade 4 neutropenia events occurred approximately 6-8 weeks after initiation of palazestrant, these were managed with dose interruptions or discontinuations and/or with colony-stimulating factors, and following dose reductions, 3 patients were able to continue palazestrant with no further recurrences of neutropenia.”
> “The mechanism underlying neutropenia is unknown, and no corresponding trends were observed in preclinical studies of palazestrant (unpublished data).”
> “Neutropenia, albeit at a lower frequency, has also been reported with fulvestrant, with grade ≥ 3 neutropenia observed in 1% to 2% of patients receiving fulvestrant monotherapy and rates of febrile neutropenia of 0 to 1% [30, 31].”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “Of the 86 patients treated, events of Grade 4 neutropenia were observed in six patients, occurring approximately 4–6 weeks into therapy.”
> “All six patients had prior exposure to CDK4/6 inhibitors.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.1.2.7.1-5"></a>

#### Neutropenia: blood count monitoring in ongoing trials

> “All ongoing studies with palazestrant include proactive monitoring of blood counts that is more frequent during first 6–8 weeks after initiation of palazestrant, with the possibility for dose reduction or interruption following the detection of grade 3 or 4 neutropenia.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.7.1-6"></a>

#### Adverse events including neutropenia: combination with ribociclib

| Related TEAE, n (%) | 120 mg + ribociclib, all grades (n = 56) | 120 mg, grade 3 | 120 mg, grade 4 | 90 mg + ribociclib, all grades (n = 16) | 90 mg, grade 3 | 90 mg, grade 4 |
| --- | --- | --- | --- | --- | --- | --- |
| Neutropenia | “47 (84%)” | “28 (50%)” | “5 (9%)” | “13 (81%)” | “9 (56%)” | “2 (16%)” |
| WBC decrease | “24 (43%)” | “9 (16%)” | “1 (2%)” | “6 (38%)” | “4 (25%)” | “0” |
| Nausea | “41 (73%)” | “2 (4%)” | “0” | “11 (69%)” | “1 (6%)” | “0” |
| Fatigue | “30 (54%)” | “3 (5%)” | “0” | “9 (50%)” | “0” | “0” |
| Diarrhea | “24 (43%)” | “2 (4%)” | “0” | “4 (25%)” | “0” | “0” |
| Vomiting | “21 (38%)” | “1 (2%)” | “0” | “4 (25%)” | “0” | “0” |
| Electrocardiogram QT prolonged | “16 (29%)” | “4 (5%)” | “0” | “4 (25%)” | “1 (6%)” | “0” |
| AST increased | “15 (27%)” | “2 (4%)” | “0” | “3 (19%)” | “0” | “0” |

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

> “2 patients had a dose reduction of palazestrant only; 1 due to nausea and 1 due to neutropenia”
> “8 patients had a dose reduction of both treatments; 23 patients had a dose reduction of ribociclib.”
> “The most common cause for dose reduction was neutropenia.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-2.1.2.7.1-7"></a>

#### Adverse events including neutropenia: combination with palbociclib

| TEAE, n (%) | All grades (N = 46) | Grade 3 | Grade 4 |
| --- | --- | --- | --- |
| Neutropenia | “40 (87)” | “28 (61)” | “5 (11)” |
| Nausea | “26 (57)” | “0” | “0” |
| Vomiting | “17 (37)” | “0” | “0” |
| Anemia | “12 (26)” | “1 (2)” | “0” |
| Diarrhea | “11 (24)” | “0” | “0” |

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

> “Neutropenia incidence was similar to the PALOMA-3 study; it was reversible in all patients and the timing was generally consistent with the palbociclib-related neutropenia.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.1.2.7.1-8"></a>

#### Bradycardia and photopsia: phase 1/2 monotherapy

> “TEAEs of oral SERDs observed in less than 10% of patients treated at the RP2D of palazestrant included bradycardia (9%) and photopsia (5%); all bradycardia and photopsia events were grade 1, and there were no dose modifications, interruptions, or discontinuations due to these events.”
> “Additionally, unlike with other SERDs that have reported rates of up to 45% for bradycardia and 56% for photopsia, the incidence of bradycardia and photopsia was lower with palazestrant (9% and 5%, respectively) [25, 28, 29].”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.7.1-9"></a>

#### QTc interval: monotherapy and combination with ribociclib

> “There were no clinically significant changes in the QT interval corrected by the Fridericia formula (QTcF) in any patients treated with palazestrant, and no QTcF values exceeded 500 ms.”
> “Patients who received medications with a known risk of QT interval prolongation or Torsades de Pointes were not permitted to enroll in order to allow comprehensive assessment of QT interval prolongation in the study.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “No QTcF values of >500 ms were observed at any time point.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

> “Screening QTcF <450 ms, resting heart rate 50-90 beats/min”

Source: [Borges et al. (2024b)](https://ir.olema.com/static-files/dfb83ebb-df49-47a3-a585-ec416cc48954)

> “Significant cardiovascular disease”
> “Significant ECG abnormalities”

Source: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

<a id="topic-2.1.2.7.1-10"></a>

#### Gastrointestinal toxicity: nausea, vomiting, and diarrhea

> “The most frequently reported TRAEs were gastrointestinal events and fatigue, which have also been commonly reported with SERDs and selective ER covalent antagonists (SERCAs) [24–27].”
> “In this study, palazestrant was administered in the fasted state, proton pump inhibitors and most common antiemetic medications were not permitted, and the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events.”
> “In patients treated with the RP2D of palazestrant, the rate of treatment-related diarrhea of any grade was 13%, and there were no grade ≥ 3 events.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “In OPERA-01 pivotal Phase 3 trial, patients are receiving tablet formulation instead of the capsules utilized in current dataset”
> “Expected to reduce rate and grade of nausea and vomiting”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.1.2.7.1-11"></a>

#### Hepatic laboratory abnormalities

> “In this study, DLTs included any treatment-related fatal adverse event (AE); grade ≥ 3 nonhematologic toxicity (including nausea, vomiting, diarrhea not resolving within 3 days with optimal treatment, and fatigue lasting > 7 days); grade 3 neutropenia (with fever and/or infection); grade 3 thrombocytopenia (with bleeding); grade ≥ 4 hematologic toxicity; grade ≥ 2 AEs that resulted in treatment discontinuation or interruption for at least a week (during cycle 1) or a delay of cycle 2 for at least a week; and protocol-defined elevations of aspartate aminotransferase (AST) or alanine aminotransferase (ALT).”
> “Seven patients discontinued palazestrant due to AEs, of which 5 were assessed as related to palazestrant: grade 4 febrile neutropenia with no evidence of infection, grade 4 neutropenia, grade 3 nausea, grade 3 international normalized ratio increase, and grade 2 fatigue.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

| TEAE, 120 mg (n = 83) | Grade 1 | Grade 2 | Grade 3 | Grade 4 | All (%) |
| --- | --- | --- | --- | --- | --- |
| AST increased | “10” | “2” | “1” | “0” | “13 (16%)” |

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.1.2.7.1-12"></a>

#### Venous thromboembolism

> “Patients were excluded from all phases of the study if they had impaired cardiac function, cerebral vascular disease, or a recent thromboembolic event”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “History of a pulmonary embolism, or deep venous thrombosis within the last 6 months, or subject has an increased risk of thrombosis as determined by the investigator.”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

> “Cerebral vascular disease, pulmonary embolism, DVT <6 months prior to the first dose of study drug, or increased risk of thrombosis”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.7.1-13"></a>

#### Discontinuations due to adverse events: phase 1/2 monotherapy

> “Reasons for treatment discontinuation included radiographic disease progression (n = 78 [67.2%]), clinical disease progression (i.e., without disease progression per RECIST v1.1) (n = 11 [9.5%]), AEs (n = 7 [6.0%]), withdrawal of consent (n = 4 [3.4%]), and other reasons (n = 2 [1.7%]).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.7.1-14"></a>

#### Safety assessments and independent data monitoring in OPERA-01

> “Safety and tolerability (AEs, SAEs, dose modifications, clinical laboratory parameters, ECGs, performance status, and vital sign measurements)”
> “Adverse event (AE) severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.”
> “An independent data monitoring committee (IDMC), comprising medical and statistical representatives not involved in the trial, is monitoring the safety, efficacy, and conduct of the trial.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.7.1-15"></a>

#### Class context: dyslipidemia and embryo-fetal toxicity with elacestrant

> “5.1 Dyslipidemia Hypercholesterolemia and hypertriglyceridemia occurred in patients taking ORSERDU at an incidence of 30% and 27%, respectively.”
> “Monitor lipid profile prior to starting and periodically while taking ORSERDU.”
> “Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman.”

Source: [Orserdu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217639s007lbl.pdf)

<a id="topic-2.1.2.7.1-16"></a>

#### Class context: QTc prolongation and bradycardia with camizestrant

> “ETCAMAH in combination with ribociclib, a QTc interval prolonging drug and a strong CYP3A inhibitor, or in combination with other QTc interval prolonging drugs, can increase the risk of Torsades de Pointes, other ventricular arrhythmias, and sudden death”
> “ETCAMAH causes a decrease in heart rate.”
> “In SERENA-6, bradycardia adverse events occurred in 8% of patients treated with ETCAMAH.”
> “Visual disturbances include: photopsia, blurred vision, visual field defect, decreased visual acuity, visual impairment, diplopia, photophobia and visual perseveration.”

Source: [Etcamah prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220359Orig1s000lbl.pdf)

<a id="topic-2.1.2.7.1-17"></a>

#### Class context: QTc prolongation with vepdegestrant

> “In VERITAC-2, QTc interval prolongation was reported in 10% of patients; Grade 3 occurred in 1.6% of patients.”
> “Perform an ECG prior to initiation of treatment with VEPPANU, and do not initiate VEPPANU in patients with QTc >470 msec.”

Source: [Veppanu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
